Patients with kidney cancer who took probiotic supplements of Clostridium butyricum had improved response to immunotherapy, according to a randomized phase 1 study.
Your institute does not have access to this article
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Mountzouris, K. C., McCartney, A. L. & Gibson, G. R. Br. J. Nutr. 87, 405–420 (2002).
Isa, K. et al. Hum. Exp. Toxicol. 35, 818–832 (2016).
Dizman, N. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01694-6 (2022).
Seki, H. et al. Pediatr. Int. 45, 86–90 (2003).
Stoeva, M. K. et al. Gut Microbes 13, 1–28 (2021).
Tomita, Y. et al. Cancer Immunol. Res. 8, 1236–1242 (2020).
Sivan, A. et al. Science 350, 1084–1089 (2015).
Thana, M. et al. Clin. Genitourin. Cancer https://doi.org/10.1016/j.clgc.2021.12.003 (2021).
Derosa, L. et al. Eur. Urol. 78, 195–206 (2020).
Salgia, N. J. et al. Eur. Urol. 78, 498–502 (2020).
Spencer, C. N. et al. Science 374, 1632–1640 (2021).
Derosa, L. et al. Cancer Discov. 11, 2396–2412 (2021).
L.D. declares consulting and advisory role fees from BMS, Sanofi, Astra Zeneca and was supported by Philantropia Fondation Gustave Roussy. L.Z. received research contract from Kaleido, Innovate Pharma and Pilege.
About this article
Cite this article
Derosa, L., Zitvogel, L. A probiotic supplement boosts response to cancer immunotherapy. Nat Med 28, 633–634 (2022). https://doi.org/10.1038/s41591-022-01723-4